Pharmacologic candidates for prophylaxis and therapy against coronary thrombosis include platelet antiaggregants, anticoagulants, and thrombolytic agents. As understanding of the mechanisms of thrombogenesis and thrombolysis increases, so does the ability to anticipate when and how these agents can be expected to be effective. Current trials of the thrombolytic agents are viewed in this context.